Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • News

    FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering

    Medtech developer Visioneering Technologies (ASX: VTI) may soon have its NaturalVue Multifocal (NVMF) contact lenses re-classified by the FDA which has just approved the first contact lenses which slow the progression of nearsightedness.  The FDA approval was given to CooperVision’s MiSight® 1 day contact lens which slows the progression of myopia specifically in children. The

    Read More
    Public
  • Small Cap Watch – Specialty Metals International (SEI)
    • Opinion

    Small Cap Watch – Specialty Metals International (SEI)

    Small miners, like most small-cap stocks, trade based on the announcement of milestones; Discovery of promising exploration sites, proving of reserves, and completing feasibility studies. However, usually the biggest jump in a small miner’s share price is when they announce the start of resource production. This is a milestone that many small miners don’t reach,

    Read More
    Public
  • ServTech launches virtual reality tech in Canada, capitalising on building activity
    • News

    ServTech launches virtual reality tech in Canada, capitalising on building activity

    With Toronto, currently in the midst of a mini housing boom which has seen rises in house prices and an influx of commercial development, Australian tech company ServTech Global (ASX: SVT) is set to launch their virtual reality (VR) and augmented reality (AR) software in Canada. The expansion comes via a software distribution agreement with

    Read More
    Public
  • XJO set to open flat after another US record
    • News

    XJO set to open flat after another US record

    The XJO has been toying with potential resistance at the 6,750 – 6,775 level, after breaking the level on Friday. If the XJO can break this resistance convincingly, we should eventually see the XJO continue higher towards the all-time high level at 6,875, which should be the next resistance. If we fall through 6,750, the

    Read More
    Public
  • HeraMED shares surge 51% following FDA approval for fetal heart monitor
    • News

    HeraMED shares surge 51% following FDA approval for fetal heart monitor

    Medtech company HeraMED (ASX: HMD) has seen a major spike in investor confidence after securing clearance from the US Food and Drug Administration (FDA) for HeraBEAT US – their fetal ultrasonic heart monitor.  Intended to detect, display and replay heart beats from as early as 12 weeks into pregnancy, the handheld device was developed in

    Read More
    Public
  • Medical cannabis adoption trend continuing in UK after Althea Group secures key licence
    • News

    Medical cannabis adoption trend continuing in UK after Althea Group secures key licence

    Australian-based Medical Cannabis producer and supplier, Althea Group (ASX: AGH), have announced this morning that their Bristol-based medical clinic site has secured a licence from a UK independent health and social care regulator. The news suggests that medical cannabis is becoming increasingly accepted in the UK as a treatment option for chronic health conditions.  Wholly

    Read More
    Public
  • «
  • ‹
  • 642
  • 643
  • 644
  • 645
  • 646
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.